Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation

Biomaterials. 2016 Feb:79:88-100. doi: 10.1016/j.biomaterials.2015.11.040. Epub 2015 Dec 2.

Abstract

MHC class I (MHC I) antigen presentation of exogenous antigens (so called "cross presentation") is a central mechanism of CD8(+) cytotoxic T lymphocyte (CTL) responses essential for successful vaccine-based cancer immunotherapy. The present study constructed amphiphilic pH-sensitive galactosyl dextran-retinal (GDR) nanogels for cancer vaccine delivery, in which dextran was conjugated with all-trans retinal (a metabolite of vitamin A) through a pH-sensitive hydrazone bond, followed by galactosylation to acquire dendritic cell (DC)-targeting ability. Our results showed that pH-sensitive GDR nanogel was a self-adjuvanted vaccine carrier that not only promoted DC maturation through activating retinoic acid receptor (RAR) signaling, but also facilitated antigen uptake and cytosolic antigen release in DCs. Furthermore, pH-sensitive GDR nanogel effectively augmented MHC I antigen presentation and evoked potent anti-cancer immune responses in vivo. More importantly, we first reported that nanoparticle-triggered lysosome rupture could directly induce ROS production in DCs, which was found to be essential for augmenting proteasome activity and downstream MHC I antigen presentation. Hence, DC-targeted pH-sensitive GDR nanogels could be a potent delivery system for cancer vaccine development. Triggering lyososomal rupture in DCs with pH-sensitive nanoparticles might be a plausible strategy to elevate intracellular ROS production for promoting antigen cross presentation, thereby improving cancer vaccine efficacy.

Keywords: Lysosomal rupture; MHC I antigen presentation; Proteasome activity; ROS; pH-sensitive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines / administration & dosage*
  • Cells, Cultured
  • Chemotherapy, Adjuvant / methods
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / chemistry
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology
  • Histocompatibility Antigens Class I / immunology*
  • Hydrogen-Ion Concentration
  • Immunotherapy / methods
  • Lysosomes / chemistry*
  • Mice
  • Mice, Inbred C57BL
  • Nanocapsules / administration & dosage*
  • Nanocapsules / chemistry
  • Neoplasms, Experimental / immunology
  • Neoplasms, Experimental / therapy*
  • Reactive Oxygen Species / immunology*
  • Tissue Distribution
  • Treatment Outcome

Substances

  • Cancer Vaccines
  • Delayed-Action Preparations
  • Histocompatibility Antigens Class I
  • Nanocapsules
  • Reactive Oxygen Species